ESMO 2023 Insights: "Phase 3 RUBY Trial - Dostarlimab + Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer - Analysis of PFS & OS Outcomes by Molecular Classification"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ESMO 2023 Insights: "Phase 3 RUBY Trial - Dostarlimab + Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer - Analysis of PFS & OS Outcomes by Molecular Classification"

By Insights from 2023 ESMO Annual Meeting FEATURING Mansoor Raza Mirza

0 views

October 26, 2023

Comments 0

First-line Maintenance Treatment Option in Patients With HRD-Positiv…

Feat. S. Lewin

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn

ASCO® 2024 Summary: "Gynecologic Oncology Updates"

Feat. R. Salani

17:50

AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde

14:45

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Gynecological Cancers Highlights"

Feat. M. Raza Mirza

06:07

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Key Updates in Gynecological Cancers"

Feat. M. Raza Mirza

04:43

Treatment Approach for Advanced Ovarian Cancer

The Role Of Folate Receptor Alpha In Ovarian Cancer

Feat. D. M. O'Malley

09:41

Insights from 2024 SGO Annual Meeting

SGO 2024 Summary: "Key Updates in Endometrial Cancer"

Feat. M. Raza Mirza

08:16

Insights from 2024 SGO Annual Meeting

SGO 2024 Insights: "GOG-0258 - OS by Molecular Classification W…

Feat. A. Clements

13:15

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Timing of Debulking Surgery in Advanced En…

Feat. A. Karam

11:19

Insights from 2024 SGO Annual Meeting

SGO 2024 Insights: "RUBY Part 1 & Part 2 Trial - Dostarlima…

Feat. M. Raza Mirza

15:14

Brian Slomovitz

Update in Vulvar and Vaginal Cancer

16:37

Total Health

2024 Updates in Uterine/Endometrial Cancer

Feat. T. Tillmanns

17:20

UCLA Health

Antibody Drug Conjugates in Gynecologic Oncology: From Bench to Beds…

Feat. G. Konecny

20:52

Yale Cancer Center

Classification, Diagnosis and Treatment of Endometrial Cancer in 2024

Feat. P. Dottino

12:55

Scripps Health

Integrating Immunotherapy Into the Treatment of Endometrial Cancer

Feat. A. Wright

08:45

Total Health

Recent Highlights in Endometrial Cancer

Feat. B. Slomovitz

07:25

Insights from 2024 SGO Annual Meeting

SGO 2024 Insights: "The Use of Rucaparib vs. Placebo Maintenanc…

Feat. B. Corr

10:35

UCLA Health

Updates in Endometrial Cancer

Feat. R. Salani

07:24

Fengting Yan

Year in Review: Endometrial Cancer

18:46

OncoAlert

Systemic Therapies for Uterine Leiomyosarcoma

Feat. I. Ray-Coquard

01:41

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Unveiling the Unique Identity of Clear-Cel…

Feat. F. Blanc-Durand

Login

Login

Join VuMedi

ESMO 2023 Insights: "Phase 3 RUBY Trial - Dostarlimab + Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer - Analysis of PFS & OS Outcomes by Molecular Classification"

Recommended